Amgen, Pfizer, Eli Lilly, Merck, and Novo Nordisk Set to Report Q2 Earnings This Week

Earnings
โดย Zacks Investment Research·Read original
Summary · why it matters

Five major pharmaceutical companies—Amgen, Pfizer, Eli Lilly, Merck, and Novo Nordisk—are scheduled to release their second-quarter 2026 earnings this week. Amgen reports after the market closes on August 4, with consensus estimates of $9.44 billion in sales and $5.60 per share in earnings, driven by volume growth from products like Repatha and Tezspire but offset by declining Prolia and Xgeva sales. Pfizer reports before the opening bell on August 4, with estimates of $14.45 billion in revenue and 68 cents per share, as higher sales of the Vyndaqel family and Eliquis are partially offset by lower COVID-19 product revenues. Eli Lilly reports before the opening bell on August 5, with estimates of $20.26 billion in sales and $6.71 per share, fueled by strong demand for Mounjaro and Zepbound despite lower pricing. Merck also reports before the opening bell on August 4, with sales estimated at $16.33 billion and a loss of 26 cents per share, as Keytruda and new products like Winrevair drive growth while Gardasil sales decline. Novo Nordisk reports before the opening bell on August 5, with estimates of $11.27 billion in sales and 82 cents per share, led by diabetes and obesity care products Ozempic, Wegovy, and Rybelsus.

Impact on stocks 6

Biotech & Genomic Medicine▲ · 5 stocks
Amgen Inc
AMGN
± MixedCapitalrelevance

Q2 earnings report with mixed drivers: volume growth from Repatha and Tezspire offset by declining Prolia and Xgeva sales.

Eli Lilly and Company
LLY
▲ PositiveDemandrelevance

Strong demand for Mounjaro and Zepbound expected to drive Q2 sales despite lower pricing.

Merck & Company Inc
MRK
± MixedCapitalrelevance

Q2 earnings expected to show growth from Keytruda and Winrevair but decline in Gardasil sales, with a projected loss.

Novo Nordisk A/S
NOV
▲ PositiveDemandrelevance

Q2 earnings expected to be led by diabetes and obesity care products Ozempic, Wegovy, and Rybelsus.

Pfizer Inc
PFE
± MixedCapitalrelevance

Q2 earnings expected to show higher sales of Vyndaqel and Eliquis offset by lower COVID-19 product revenues.

Critical Materials & Supply Chain▲ · 1 stocks
© 2026 MarketDXNews